dsip sbir topics Topic Releases – Army SBIR|STTR Program DoD Pre-Releases SBIR 25.1/STTR 25.A

Bogale TA, Faustini G, Longhena F, Mitola S, Pizzi M, Bellucci A (2021) Alpha-synuclein in the regulation of brain endothelial and perivascular cells: gaps and future perspectives

Transparent pricing & monitoring : advanced medicine shouldnt be mysterious or unaffordable

"The FDA submission of CagriSema marks an important milestone and signals a new era in weight management, reinforcing Novo Nordisk's long-standing commitment to serving people living with obesity through innovation and science," said Mike Doustdar, president and CEO of Novo Nordisk

Evolution of health care in turner syndrome

[DOI] [PubMed] [Google Scholar] 69

The FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which identifies bulk drug substances that outsourcing facilities may use in compounding when there is a clinical need